ClinicalTrials.gg
Status unknownNCT05633433Updated Jan 9, 2023

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

A Phase 2/3 interventional study of Azvudine and Placebo in SARS-CoV-2 Infection, sponsored by Shanghai Henlius Biotech. Status unknown at 10 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-09.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2/3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in COVID-19 with a site in Malaysia — 2 open to participants now, 2 under way, 1 of them phase 3. COVID-19 · Malaysia.

Planned enrollment
10th of 24
1,550 · median 828
Started
2022
with 5 others
Phase 2/3
5 of 40
none open now
Registered
38th of 40
by date

Among the 40 studies in COVID-19 with a site in Malaysia, this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2022, is one of 5 in phase 2/3, and was the 38th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 40 studies in COVID-19 with a site in Malaysia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in COVID-19 with a site in Malaysia, or all of them as a file.
02

Study summary

A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2

Read the detailed description

The study has two parts:

Part 1 is a multicentre, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of Azvudine versus placebo in preventing SARS-CoV-2 infection in household contacts with SARS-CoV-2 infection individuals. The population of part 1 will consist of approximately 450 adults with household contact exposure to individuals with a confirmed SARS-CoV-2 infection.A phase III study will be further conducted if any of the treatment groups reduce SARS-CoV-2 infection rate (Relative risk reduction) > 50% compared with the placebo group.

Part 2 is a multicentre, randomized, double-blind, placebo-controlled phase III clinical study. The subject sample size will be calculated based on the results of the Phase II trial.

Phase II and phase III studies have the same objectives and primary/secondary end points. The primary endpoint is the proportion of subjects with positive SARS-CoV-2 RT-PCR assay in 7 days. Nasopharyngeal swabs will be collected at D2, D4, D7, D10, and D14 by RT-PCR to confirm SARS-CoV-2 infection.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years old at the signing of .
  2. Household contacts of individual with symptomatic COVID-19. Symptomatic COVID-19 cases (index case) to be identified as those symptomatic and recently tested (rapid antigen test or RT-PCR) positive for SARS-CoV-2 and must fulfill the following criteria 1) collection of the first positive SARS-CoV-2 test sample less than 48 hours before randomization, 2) have at least one symptom attributable to COVID-19.
  3. RT-PCR test negative (with nasopharyngeal [NP] swab samples) OR rapid antigen test negative at the time of screening and without any suspicious COVID-19 symptoms within 2 weeks before randomization.
  4. Subject expects to be living in the same household with the symptomatic COVID-19 cases during the whole study period.
  5. Willing and able to comply with study visits and study-related procedures/assessments.
  6. Provide informed consent signed by study subject or legally acceptable representative.

Exclusion criteria

Exclusion Criteria:

  1. Subject with a history of SARS-CoV-2 vaccinations within 6 months before randomization.
  2. Subject with a history of SARS-CoV-2 infection within 6 months before randomization.
  3. (ALT) or aspartate aminotransferase (AST) >3× (ULN) ,or total (TBIL) >2×ULN.
  4. (Ccr, calculated by Cockcroft-Gault equation)\<60 ml/min or Creatinine >1.2×ULN.
  5. With any serious infection requiring systemic anti-infective therapy within 14 days before randomization.
  6. Allergic to the agent or any components of the formulation.
  7. Pregnant or breast-feeding women.
  8. Previous administration of any antiretroviral drugs (e.g., antiretroviral drugs for , , or ) within 7 days before randomization.
  9. Women of who are unwilling to practice highly effective during the study, and for at least 6 months after the study; Sexually active men who are unwilling to use medically acceptable birth control during the study period.
  10. Have other conditions not suitable for inclusion as judged by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,550 participants (estimated)

Study arms

  • Experimental
    cohort A (Phase II)

    Azvudine 5 mg, QD PO, D1-D7

    Drug: Azvudine

  • Experimental
    cohort B (Phase II)

    Azvudine 3 mg + placebo 2 mg, QD PO, D1-D7

    Drug: Azvudine · Drug: Placebo

  • Placebo comparator
    cohort C (Phase II)

    placebo 5 mg, QD PO, D1-D7

    Drug: Placebo

  • Experimental
    Arm 1 (Phase III)

    Azvudine, dose to be determined according to phase II, QD PO, D1-D7

    Drug: Azvudine

  • Placebo comparator
    Arm 2 (Phase III)

    Placebo, dose to be the same as Arm1, QD PO, D1-D7

    Drug: Placebo

Interventions

  • Azvudine is a novel nucleoside reverse transcriptase inhibitor.

    Also known as: FNC

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Efficacy-Incidence of SARS-CoV-2 infection in 7 days

    The incidence of SARS-CoV-2 infection (RT-PCR positive) up to 7 days from 2 days after administration of Azvudine for prevention of SARS-CoV-2 infection.

    Time frame: Day 2 to Day 7

Secondary outcomes

  1. Incidence of asymptomatic SARS-CoV-2 infection in 7 days

    The incidence of asymptomatic SARS-CoV-2 infection (RT-PCR positive) up to 7 days from 2 days after administration of Azvudine for prevention of SARS-CoV-2 infection.

    Time frame: Day 2 to Day 7

  2. Incidence of symptomatic SARS-CoV-2 infection in 7 days

    The incidence of symptomatic SARS-CoV-2 infection (RT-PCR positive) up to 7 days from 2 days after administration of Azvudine for prevention of SARS-CoV-2 infection.

    Time frame: Day 2 to Day 7

  3. Incidence of SARS-CoV-2 infection in 14 days

    The incidence of SARS-CoV-2 infection (RT-PCR positive) up to 14 days from 2 days after administration of Azvudine for prevention of SARS-CoV-2 infection.

    Time frame: Day 2 to Day 14

  4. Incidence of asymptomatic SARS-CoV-2 infection in 14 days

    The incidence of asymptomatic SARS-CoV-2 infection (RT-PCR positive) up to 14 days from 2 days after administration of Azvudine for prevention of SARS-CoV-2 infection.

    Time frame: Day 2 to Day 14

  5. Incidence of symptomatic SARS-CoV-2 infection in 14 days

    The incidence of SARS-CoV-2 infection (RT-PCR positive) up to 14 days from 2 days after administration of Azvudine for prevention of SARS-CoV-2 infection.

    Time frame: Day 2 to Day 14

  6. Incidence of severe COVID-19

    To describe the incidence of severe COVID-19 up to 28 days after administration of Azvudine for prevention of SARS-CoV-2 infection.

    Time frame: Day 1 to Day 28

  7. Incidence of all-cause mortality

    To describe the incidence of all-cause mortality during the 28 days after administration of Azvudine for prevention of SAR-CoV-2 infection.

    Time frame: Day 1 to Day 28

  8. Time to SARS-CoV-2 infection

    The time to SARS-CoV-2 infection after the the first dose of Azvudine will be evaluated in the RT-PCR positive participants.

    Time frame: Day 1 to Day 28

  9. Duration of symptoms

    Duration of symptoms in participants with COVID-19.

    Time frame: Day 1 to Day 28

  10. Adverse events

    Number of participants with adverse events after administration of Azvudine will be evaluated.

    Time frame: Day 1 to Day 28

  11. Maximum serum concentration (Cmax)

    The Cmax of Azvudine after administration in participants will be evaluated.

    Time frame: Day 1 to Day 28

  12. Time to reach maximum serum concentration (Tmax)

    The Tmax of Azvudine after administration in participants will be evaluated.

    Time frame: Day 1 to Day 28

  13. Terminal half-life (T1/2)

    The T1/2 of Azvudine after administration in participants will be evaluated.

    Time frame: Day 1 to Day 28

  14. Apparent total clearance (CL/F)

    The CL/F of Azvudine after administration in participants will be evaluated.

    Time frame: Day 1 to Day 28

  15. Apparent volume of distribution based on terminal phase (Vz/F)

    The Vz/F of Azvudine after administration in participants will be evaluated.

    Time frame: Day 1 to Day 28

  16. Area under the concentration-time curve from time 0 to the last concentration-measurable time point (AUC0-t)

    The AUC0-t of Azvudine after administration in participants will be evaluated.

    Time frame: Day 1 to Day 28

  17. Area under the concentration-time curve from time 0 to infinity (AUC0-∞)

    The AUC0-∞ of Azvudine after administration in participants will be evaluated.

    Time frame: Day 1 to Day 28

07

Study locations

1 of 10 sites recruiting
  • University of Malaya Medical Centre
    Kuala Lumpur, Malaysia
    Not yet recruiting
    • Mohd Idzwan bin Zakaria, Ph.D. · Contact03-79493209
    • Mohd Idzwan bin Zakaria, Ph.D. · Principal investigator
  • International Islamic University Malaysia
    Kuantan, Malaysia
    Not yet recruiting
    • Nur Syazwani Binti Jamhuri, Dr. · Contact
    • Nur Syazwani Binti Jamhuri, Dr. · Principal investigator
  • ALPS Medical Center
    Shah Alam,, Malaysia
    Not yet recruiting
    • Benjamin George, Dr. · Contact
    • Benjamin George, Dr. · Principal investigator
  • Klinik Kesihatan Cheras
    Shah Alam, Malaysia
    Not yet recruiting
    • Siti Shafiatun Siti Shafiatun, Dr. · Contact
    • Siti Shafiatun Siti Shafiatun, Dr. · Principal investigator
  • Klinik Kesihatan Greentown
    Shah Alam, Malaysia
    Not yet recruiting
    • V. Paranthaman, Dr. · Contact
    • V. Paranthaman, Dr. · Principal investigator
  • Klinik Kesihatan Kuala Kedah
    Shah Alam, Malaysia
    Not yet recruiting
    • Fazlin Suhana Othman, Dr. · Contact
    • Fazlin Suhana Othman, Dr. · Principal investigator
  • Klinik Kesihatan Mahmoodiah
    Shah Alam, Malaysia
    Not yet recruiting
    • Wan Fadhilah Binti Wan Ismail, Dr. · Contact
    • Wan Fadhilah Binti Wan Ismail, Dr. · Principal investigator
  • Cebu Doctors' University Hospitol
    Cebu City, Philippines
    Recruiting
    • Gerard S. Garcia, M.D. · Contact
    • Gerard S. Garcia, M.D. · Principal investigator
  • Perpetual Succour Hospital
    Cebu City, Philippines
    Not yet recruiting
    • Jemela Anne Sanchez, Dr. · Contact
    • Jemela Anne Sanchez, Dr. · Principal investigator
  • University of the East Ramon Magsaysay Memorial Medical Center
    Quezon City, Philippines
    Not yet recruiting
    • Nina Marnie Beltran-Yap, M.D. · Contact
    • Nina Marnie Beltran-Yap, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Jun 2024, 17 months after the start.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 17 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 1, 2022
StartActual
Dec 29, 2022
Primary completionEst.
Jun 15, 2024
CompletionEst.
Jul 15, 2024
Last update
Jan 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05633433
Collaborators
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., HeNan Sincere Biotech Co., Ltd
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Dec 29, 2022
Primary completion
Jun 15, 2024 (estimated)
Completion
Jul 15, 2024 (estimated)
Last update
Jan 9, 2023

Study contacts

Gerard S. Garcia, M.D.
Contact
cduhrec@gmail.com
+63324169341
Gerard S. Garcia, M.D.
principal investigator · Cebu Doctor's University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azvudine

Start the discussion